BDBM475631 US10851102, Example 24::US11339160, Ex No. 24

SMILES CCc1cc(O)c(F)cc1-c1cc(OCC2CN(C2)C(=O)\C=C\CN(C)C)c2cncn2c1

InChI Key InChIKey=ZBRPMYQBIFVPLF-UHFFFAOYSA-N

Data  8 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 475631   

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: <0.100nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: <0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: >100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: >100nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: >100nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: >100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: >100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM475631(US10851102, Example 24 | US11339160, Ex No. 24)
Affinity DataKi: >100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/29/2022
Entry Details
Go to US Patent